Proteomics International Laboratories (PIQ) Short Interest
Proteomics International Laboratories (ASX:PIQ) had 0.67% of shares reported as short positions as of 24 Aug 2026, representing 1,109,472 shares. Proteomics International Laboratories operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Proteomics International Laboratories
Proteomics International Laboratories Ltd (ASX:PIQ) is a medical technology company specializing in predictive diagnostics and bio-analytical services. They focus on proteomics, the industrial-scale study of protein structure and function, to develop novel diagnostic tests like PromarkerD, PromarkerEndo, and PromarkerEso, aiming to bring these to global markets.
Short position
Proteomics International Laboratories (ASX:PIQ) has 0.67% of its shares on issue reported as short positions as of 24 Aug 2026, or about 1,109,472 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.15 percentage points. PIQ is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PIQ intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Proteomics International Laboratories
Latest PIQ news
All news- Proteomics secures Australian patent for endometriosis test
theage
- Proteomics International Laboratories Secures Australian Patent Acceptance for PromarkerEndo
smallcaps
- Australian patent for PromarkerEndo
asx
- Proteomics International (ASX:PIQ) Faces Funding Test as PromarkerD Advances - Kalkine
googlenews
- Change in substantial holding
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PIQ
Start a research thread or post the first pulse update